Camzyos

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Camzyos

What it is

Mavacamten is a cardiac myosin inhibitor, the first of a new kind of heart medicine: it reduces the excessive squeezing force of the heart muscle by limiting how many myosin motor units engage. It is used for obstructive hypertrophic cardiomyopathy, an inherited thickening of the heart wall, to relieve symptoms. It is sold as Camzyos.

How genes come into it

Mavacamten is broken down mainly by the liver enzyme CYP2C19, with help from CYP3A4. People with no working CYP2C19 copies (poor metabolizers) have several times the usual exposure and a much longer half-life, so the drug builds up more. The US FDA lists the pair as affecting safety, and DPWG has published a guideline on CYP2C19 and mavacamten.

Published guidelines

Clinical guidelines that name a gene for Camzyos. They sort people into groups by the gene copies they carry.

DPWG guideline: CYP2C19. Ultrarapid Metabolizer · Rapid Metabolizer · Normal Metabolizer · Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer · Indeterminate.

US FDA: CYP2C19. Likely Intermediate Metabolizer · Intermediate Metabolizer · Likely Poor Metabolizer · Poor Metabolizer. Data that Indicate a Potential Impact on Safety or Response.

What research found

Every published finding on gene variants and Camzyos. Upload your DNA file to see which of these rows apply to you.

Metabolism (1 finding)

Studies of how quickly the body processes this medication.

CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17: CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased exposure to mavacamten in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer and rapid metabolizer phenotype) .

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Accupril (ACE Inhibitors)

ACE Inhibitors (class) (ACE Inhibitors)

Acenocoumarol (Anticoagulants)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com